Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportGeneral Clinical Specialties

Loss of MIBG positivity following induction chemotherapy with a persisting sizable residual mass lesion corresponds to absence of a significant amount of viable tumour remaining

Sugama Chicklore, Neil Sebire and Lorenzo Biassoni
Journal of Nuclear Medicine May 2012, 53 (supplement 1) 260;
Sugama Chicklore
1Nuclear Medicine, Guy's and St. Thomas' Hospital NHS Trust, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neil Sebire
2Department of Histopathology, Great Ormond Street Hospital for Children, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorenzo Biassoni
3Department of Nuclear Medicine, Great Ormond Street Hospital for Children, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 53 no. supplement 1 260

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online November 4, 2014.

Copyright & Usage 
© 2012

Author Information

  1. Sugama Chicklore1,
  2. Neil Sebire2 and
  3. Lorenzo Biassoni3
  1. 1Nuclear Medicine, Guy's and St. Thomas' Hospital NHS Trust, London, United Kingdom
  2. 2Department of Histopathology, Great Ormond Street Hospital for Children, London, United Kingdom
  3. 3Department of Nuclear Medicine, Great Ormond Street Hospital for Children, London, United Kingdom

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: November 2014 to April 2025

AbstractFullPdf
Nov 2014100
Mar 2015100
Jun 2015700
Jul 2015500
Sep 2015700
Nov 2015200
Dec 2015100
Jun 2016200
Jul 2016100
Oct 2016100
Nov 2016100
Feb 2017100
Mar 2017400
Apr 2017300
May 2017100
Jun 2017200
Jul 2017500
Nov 2017100
Jan 2018100
Feb 2018100
Mar 2018100
Apr 2018100
Sep 2018200
Dec 2018100
Jan 2019200
Apr 2019200
May 2019100
Aug 2019200
Oct 2019400
Nov 2019100
Dec 2019100
Jan 2020100
Feb 2020400
Mar 20201300
Apr 2020800
Jul 2020300
Aug 2020600
Sep 20201900
Oct 20201400
Nov 20201300
Dec 2020900
Jan 2021200
Feb 2021400
Mar 2021700
Apr 2021600
May 2021300
Jun 2021300
Jul 20211100
Aug 20212300
Sep 20211000
Oct 20211700
Nov 20214500
Dec 20213500
Jan 20225600
Feb 20221600
Mar 20221000
Apr 2022300
May 20222000
Jun 2022100
Jul 2022100
Aug 2022200
Sep 2022300
Oct 2022300
Nov 2022200
Feb 2023100
Mar 2023500
Apr 2023200
May 2023200
Jun 2023100
Jul 2023200
Aug 2023300
Sep 2023200
Oct 2023200
Nov 2023400
Dec 2023100
Jan 2024500
Feb 2024100
Mar 2024100
Apr 2024300
May 2024400
Jun 2024700
Jul 2024200
Aug 2024300
Sep 2024300
Nov 2024500
Dec 2024100
Jan 2025200
Feb 2025300
Mar 2025200
Apr 2025300
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 53, Issue supplement 1
May 2012
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Loss of MIBG positivity following induction chemotherapy with a persisting sizable residual mass lesion corresponds to absence of a significant amount of viable tumour remaining
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Loss of MIBG positivity following induction chemotherapy with a persisting sizable residual mass lesion corresponds to absence of a significant amount of viable tumour remaining
Sugama Chicklore, Neil Sebire, Lorenzo Biassoni
Journal of Nuclear Medicine May 2012, 53 (supplement 1) 260;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Loss of MIBG positivity following induction chemotherapy with a persisting sizable residual mass lesion corresponds to absence of a significant amount of viable tumour remaining
Sugama Chicklore, Neil Sebire, Lorenzo Biassoni
Journal of Nuclear Medicine May 2012, 53 (supplement 1) 260;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

General Clinical Specialties

  • 18F-FDG PET/CT Imaging of Infection and Inflammation
  • Association between diffuse F18-FDG thyroid uptake and thyroid dysfunction
  • Bone Scintigraphy in Complex Regional Pain Syndrome Type I: A Pictorial Review
Show more General Clinical Specialties

Peds II: General Diagnostic Imaging

  • Phenobarbital-enhanced hepatobiliary scintigraphy in diagnosis of biliary atresia: Two decades of experience at a tertiary center
  • Bone SPECT/CT compared to bone SPECT and conventional radiographs in pediatric spondylolysis evaluation
Show more Peds II: General Diagnostic Imaging

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire